anti-PD-1 antibody · antibody
budigalimab
2 active trials across 3 of our biomarkers, targeting PD-1. Not approved for any biomarker on marked.bio yet.
Also known as ABBV-181.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| BRAF V600E | 1 | 1 | Phase 1 |
| EGFR exon 19 deletion / L858R | 1 | 1 | Phase 1 |
| IDH1/2 mutation | 1 | 1 | Phase 1 |
Sponsors
Industry sponsors leading active biomarker-selected trials of budigalimab.
- AbbVie 2
Trials
2 of 2 trials shown
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
ABBV-706cisplatinbudigalimabcarboplatin
…euroendocrine carcinoma (LCNEC)s, SCLC transformed from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), atypical lung carcinoids, and other high-grade poorly…
EGFR exon 19 deletion / L858RIDH1/2 mutationAdvanced Solid Tumors
-
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Azirkitugbudigalimabbevacizumabtelisotuzumab adizutecan
…essed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Rego…
BRAF V600ENon-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
No trials match these filters.